UBS Group’s Intellia Therapeutics NTLA Stock Holding History

UBS Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34,000	Closed	-$2.47M	–	10723
2022 Q1	$2.47M	Buy	+34,000	New	+$2.88M	﹤0.01%	3237

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

UBS Group's NTLA Position: Q2 2026 in Review

UBS Group reduced its Intellia Therapeutics (NTLA) stake by 20% in Q2 2026, selling an estimated $7.51M and leaving 2,152,912 shares worth $36.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

UBS Group first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

UBS Group held 2,152,912 shares of Intellia Therapeutics worth $36.4M as of Q2 2026.
UBS Group sold 536,574 Intellia Therapeutics shares in Q2 2026, an estimated $7.51M.
Intellia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2068 holding.
UBS Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.